Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14538084 | 1.00 | ATM (0.48) | ATMRAB9AHPGDPOLBMAPT | |
| SCHEMBL13039605 | 0.98 | ATM (0.50) | ATMRAB9AHPGDPOLBMAPT | |
| SCHEMBL14538019 | 0.82 | ACHE (0.54) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL14538018 | 0.79 | ALDH1A1 (0.36) | ATMPOLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL5181688 | 0.78 | TPSAB1 (0.51) | POLBALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL28716383 | 0.78 | ALDH1A1 (0.50) | ATMRAB9AHPGDPOLBALDH1A1 | |
| SCHEMBL14538081 | 0.78 | L3MBTL1 (0.70) | RAB9AHPGDPOLBALDH1A1L3MBTL1 | |
| SCHEMBL1220310 | 0.77 | KMT2A (0.52) | ATMRAB9AHPGDPOLBMAPT | |
| SCHEMBL13450960 | 0.77 | KMT2A (0.52) | ATMRAB9AHPGDPOLBMAPT | |
| SCHEMBL15919877 | 0.77 | ATM (0.48) | ATMRAB9AHPGDPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIV STRASBOURG (FR) | 2017-06-22 | — | — | US | disclosed |
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIV STRASBOURG (FR) | 2017-06-22 | — | — | US | disclosed |
| EP-2254880-B1 | Macrocyclic prodrug compounds useful as therapeutics | NEXGENIX PHARMACEUTICALS (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2015-12-31 | — | — | US | disclosed |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2015-12-31 | — | — | US | disclosed |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ONCOSYNERGY, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ONCOSYNERGY, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140031302-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031302-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2014-01-30 | — | — | US | disclosed |
| WO-2012052843-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2012-04-26 | — | — | WO | disclosed |
| US-20110190237-A1 | Macrocyclic Prodrug Compounds Useful as Therapeutics | NEXGENIX PHARMACEUTICALS (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2009105755-A2 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | NEXGENIX PHARMACEUTICALS (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | ATM 137/4885RAB9A 1536/4885HPGD 1584/4885 |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | ATM 141/4885RAB9A 1644/4885HPGD 1313/4885 |
| US-20110190237-A1 | Macrocyclic Prodrug Compounds Useful as Therapeutics | ADCYAP1R1, CYP19A1, THOP1 | ATM 2515/4885RAB9A 3319/4885HPGD 58/4885 |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ADCYAP1R1, CYP19A1, THOP1 | ATM 2515/4885RAB9A 3319/4885HPGD 58/4885 |
| US-20140031302-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | ATM 137/4885RAB9A 1536/4885HPGD 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.